Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
NCT05846789
This study is recruiting at 7 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab biosimilar in Black and non-Black patients with metastatic triple negative and ER-positive, HER2-negative breast cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Breast Cancer
- Triple Negative Breast Cancer
- Estrogen-receptor-low Breast Cancer
- ER Positive, HER2 Negative Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Kathy Miller
- Last updated on ClinicalTrials.gov
- September 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 1
- Emory University · Atlanta, GA
Indiana · 3
- IU Health Joe and Shelly Schwarz Cancer Center · Carmel, IN
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center · Indianapolis, IN
- Sidney and Lois Eskenazi Hospital · Indianapolis, IN
Kentucky · 1
- University of Kentucky-Lexington · Lexington, KY
New York · 1
- Roswell Park Comprehensive Cancer Center · Buffalo, NY
North Carolina · 1
- Duke University · Durham, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.